Plain-English translation of NCT07299422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called SHR-2173, given by injection, to see if it can help people with active systemic lupus erythematosus (SLE) — an autoimmune disease where the body attacks its own tissues. About 245 adults will take part, and half will receive the medication while the other half receive a placebo (inactive injection) so doctors can compare how well the treatment works.
People with lupus often struggle with the disease even while taking standard treatments, and their symptoms can significantly impact their daily lives. This trial is testing whether this medication could offer a new treatment option to help people with active lupus gain better control of their symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll have a 4-week screening period where doctors will confirm you have active lupus and check that you're eligible. Then you'll be randomly assigned to either receive the new medication or a placebo injection — you won't know which one you get. You'll receive injections over a 24-week treatment period, followed by a 24-week maintenance period to see how long the benefits last. Throughout the trial, you'll attend regular visits for blood tests and check-ins with your doctor, plus a final 12-week follow-up to make sure you're doing well.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China